Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NCOA4-RET fusion
i
Other names:
NCOA4, Nuclear Receptor Coactivator 4, Androgen Receptor-Associated Protein Of 70 KDa, 70 KDa Androgen Receptor Coactivator, RET-Activating Gene ELE1, 70 KDa AR-Activator, NCoA-4, ARA70, ELE1, RFG, Androgen Receptor Coactivator 70 KDa Protein, Ret-Activating Protein ELE1, Ret Fused, PTC3, RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-On
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5979
;
8031
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
RET fusion (62)
KIF5B-RET fusion (19)
CCDC6-RET fusion (16)
TRIM33-RET fusion (3)
EML4-RET fusion (2)
RET-RPP38 fusion (2)
CCDC6-RET fusion + RET-NRG3 fusion (1)
KIAA1217-RET fusion (1)
KIF13A-RET fusion (1)
LINC01264-RET fusion + SEMA5A-RET fusion + CCDC6-RET fusion (1)
RET-CCDC6 fusion (1)
RET-KIF5B fusion (1)
RET-TRIM33 fusion (1)
SAMD5-RET fusion (0)
RET fusion (62)
KIF5B-RET fusion (19)
CCDC6-RET fusion (16)
TRIM33-RET fusion (3)
EML4-RET fusion (2)
RET-RPP38 fusion (2)
CCDC6-RET fusion + RET-NRG3 fusion (1)
KIAA1217-RET fusion (1)
KIF13A-RET fusion (1)
LINC01264-RET fusion + SEMA5A-RET fusion + CCDC6-RET fusion (1)
RET-CCDC6 fusion (1)
RET-KIF5B fusion (1)
RET-TRIM33 fusion (1)
SAMD5-RET fusion (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: C4 – Case Studies
lenvatinib
Sensitive
:
C4
lenvatinib
Sensitive: C4 – Case Studies
lenvatinib
Sensitive
:
C4
NCOA4-RET fusion
Thyroid Gland Carcinoma
NCOA4-RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: C4 – Case Studies
pralsetinib
Sensitive
:
C4
pralsetinib
Sensitive: C4 – Case Studies
pralsetinib
Sensitive
:
C4
NCOA4-RET fusion
Cholangiocarcinoma
NCOA4-RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive: C4 – Case Studies
pralsetinib
Sensitive
:
C4
pralsetinib
Sensitive: C4 – Case Studies
pralsetinib
Sensitive
:
C4
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: C4 – Case Studies
selpercatinib
Sensitive
:
C4
selpercatinib
Sensitive: C4 – Case Studies
selpercatinib
Sensitive
:
C4
NCOA4-RET fusion
Non Small Cell Lung Cancer
NCOA4-RET fusion
Non Small Cell Lung Cancer
RXDX-105
Sensitive: D – Preclinical
RXDX-105
Sensitive
:
D
RXDX-105
Sensitive: D – Preclinical
RXDX-105
Sensitive
:
D
NCOA4-RET fusion
Ovarian Cancer
NCOA4-RET fusion
Ovarian Cancer
FHND5071
Sensitive: D – Preclinical
FHND5071
Sensitive
:
D
FHND5071
Sensitive: D – Preclinical
FHND5071
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.